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Oxidative damage andmitochondrial dysfunction are
implicated in aging and age-related neurodegenera-
tive diseases, including Huntington’s disease (HD).
Many naturally occurring antioxidants have been
tested for their ability to correct for deleterious
effects of reactive oxygen species, but often they
lack specificity, are tissue variable, and have
marginal efficacy in human clinical trials. To increase
specificity andefficacy,wehavedesigned asynthetic
antioxidant, XJB-5-131, to target mitochondria. We
demonstrate in a mouse model of HD that XJB-5-
131 has remarkably beneficial effects. XJB-5-131
reduces oxidative damage to mitochondrial DNA,
maintains mitochondrial DNA copy number, sup-
presses motor decline and weight loss, enhances
neuronal survival, and improves mitochondrial func-
tion. The findings poise XJB-5-131 as a promising
therapeutic compound.INTRODUCTION
Defective mitochondria (MT) are implicated in the pathogenesis
of neurodegenerative diseases including Alzheimer’s disease
(AD) (Huang and Mucke, 2012), Parkinson’s disease (PD) (Exner
et al., 2012), and Huntington’s disease (HD) (Johri and Beal,
2012). In all of these disorders, accumulation of oxidative
damage is involved (Exner et al., 2012; Huang and Mucke,
2012; Johri et al., 2011), but there are no effective therapeutics
(Hersch and Rosas, 2008; Mangialasche et al., 2010). MT are
the primary intracellular source of reactive oxygen species
(ROS) and the main target for oxidative damage (Lin and Beal,
2006). Thus, dietary supplements of naturally occurring antioxi-
dants such as vitamin E and coenzyme Q10 (CoQ10) have beenCell Reused in mice and in human clinical trials to alleviate the delete-
rious effects of MT-dependent ROS production (Dumont et al.,
2011; Littarru and Tiano, 2010). In general, however, their effi-
cacy has been marginal or tissue variable (Kwong et al., 2002;
Sohal and Forster, 2007; Sumien et al., 2009), and it remains
controversial whether dietary supplementation of CoQ10 can
increase its steady-state level in the brain in vivo (Kwong et al.,
2002; Sohal and Forster, 2007). These observations have driven
efforts to enhance specificity and therapeutic efficacy by direct
targeting of synthetic antioxidants to MT.
XJB-5-131 is a bifunctional antioxidant that comprises a
radical scavenger, 4-hydroxy-2,2,6,6-tetramethyl piperidine-1-
oxyl nitroxide (Figure 1A, red), conjugated to a mitochondrial
targeting moiety. The targeting portion of the molecule is an
alkene peptide isostere modification of the Leu-D-Phe-Pro-
Val-Orn segment of the antibiotic gramicidin S (Hoye et al.,
2008; Wipf et al., 2005) (Figure 1A, black) that localizes to the
mitochondrial membrane. Previously, we have reported that
XJB-5-131 reduces apoptosis and enhances cell survival in
mouse embryonic cells in vitro (Wipf et al., 2005). In this work,
we tested the beneficial effects of XJB-5-131 in a mouse model
of HD. We find that XJB-5-131 significantly suppresses the
disease phenotypes and improves mitochondrial function.
RESULTS
XJB-5-131 Is Localized to MT and Improves Primary
Neuronal Survival
We evaluated the efficacy of XJB-5-131 in a mouse model of HD
harboring disease-length 150 CAG tract ‘‘knocked-into’’ both
alleles of the mouse HD gene homolog (Hdh(CAG)150/(CAG)150)
(Lin et al., 2001). These animals will be referred to hereafter as
HD150KI. To validate that XJB-5-131 targeted MT, we isolated
primary striatal neurons (embryonic day 17) from HD150KI
animals and treated them with BODIPY-FL-XJB-5-131, a de-
rivative of XJB-5-131 labeled with the fluorescent (FL) boron-di-
pyrromethene (BODIPY) (Figure 1A). Within 1 hr of incubation,ports 2, 1137–1142, November 29, 2012 ª2012 The Authors 1137
Figure 1. XJB-5-131 Is Localized to Mito-
chondria and Enhances Neuronal Survival
in a Mouse Model of HD
(A) Schematic diagram of the structure and func-
tional design of XJB-5-131 and BODIPY-fluores-
cent labeled (FL)-XJB-5-131. The structure in red
is a stable nitroxide free radical with ROS
scavenging abilities. The structure in black is
derived from a cyclopeptide antibiotic, gramicidin
S, which selectively accumulates within microbial
cell membranes. BODIPY-FL-XJB-5-131 was de-
signed to validate its mitochondrial localization.
(B) MitoTracker Deep Red (MtT, red) and BODIPY-
FL-XJB-5-131 (XJB, cyan) colabel MT in primary
striatal neurons from embryonic day 17 HD150KI
mice. The arrowheads indicate representative
MT detected by both probes. Scale bar is 10
microns.
(C) XJB-5-131 treatment (1 mM) for 1 week does
not induce measureable changes in the number
of MT in primary striatal neurons as quantified
after staining with MitoTracker Deep Red inten-
sity. The right panels are representative images.
The total number of cells analyzed per condition
is > 10,000 from three independent experiments.
Data are mean ± SEM (n = 3). Scale bar is 10
microns.
(D) XJB-5-131 treatment protects survival of pri-
mary striatal neurons after 7 days in culture. The
right panels are representative images. Scale bar
is 10 microns. Data are mean ± SEM (n = 3). **p <
0.01 using the unpaired two-tailed Student’s t test.
XJB, XJB-5-131. See also Figure S1.BODIPY-FL-XJB-5-131 crossed the plasma membrane and
stained MT in primary neurons, as verified by costaining with
MitoTracker Deep Red (Figure 1B). Treatment of freshly plated
primary neurons with XJB-5-131 (1 mM) for 7 days did not induce
measureable changes in the number ofMT (Figure 1C). However,
under these conditions, XJB-5-131 improved survival of the
primary striatal neuronal cultures derived from both HD150KI
mice (Figure 1D) and genetically matched C57BL/6 wild-type
mice (Figure S1), suggesting that accumulation of XJB-5-131
in the MT was beneficial to the primary neuronal cultures in vitro.
XJB-5-131SuppressesWeight Loss and ImprovesMotor
Performance
We tested whether XJB-5-131 had beneficial effects in vivo.
We intraperitoneally injected HD150KI mice with XJB-5-131 at
1 mg/kg three times a week up to 57 weeks, and tested whether
treatment improved the disease phenotypes in these animals.
Chronic treatment ofHD150KImice with XJB-5-131 suppressed
weight loss, a pathology commonly observed in HD patients
(Kirkwood et al., 2001). Genetically matched C57BL/6 control
animals increased in weight to an average of 44 ± 5 g at 57weeks
(Figure 2A), while age- and gender-matchedHD150KImice were
smaller (32 ± 3 g) (Figure 2A). Treatment ofHD150KI animals with
XJB-5-131 increased the averagebodymassby22% (Figure 2A).1138 Cell Reports 2, 1137–1142, November 29, 2012 ª2012 The AutEarly signs of HD pathology manifest as motor abnormalities
(Kirkwood et al., 2001). As a second test for XJB-5-131’s effi-
cacy, we measured rotarod performance and grip strength of
animals at 9, 28, and 57weeks (Figure 2B). All animals at 9weeks
performed equally well on the rotarod (Figure 2B). However,
performance in HD150KI mice declined with age, resulting
in an approximately 70% decrease by 57 weeks (Figure 2B).
Remarkably, there was no significant decline in rotarod perfor-
mance in HD150KI mice chronically treated with XJB-5-131
during the same period (Figure 2B). Furthermore, XJB-5-131
treatment led to a striking improvement in grip strength (Fig-
ure 2C). At 57 weeks, approximately 95% of the HD150KI
mice failed to grip the bar for 30 s in three trials, while at the
same age, 85% of the XJB-5-131-treated HD150KI littermates
passed the test. Collectively, these data demonstrated that
XJB-5-131 significantly reduced the disease phenotypes ob-
served in HD150KI mice.
XJB-5-131 Reduces mtDNA Damage and Maintains
mtDNA Copy Number
MT are the primary intracellular source of ROS and the main
target for oxidative damage (Lin and Beal, 2006; Woo and
Shadel, 2011). If the beneficial effects of XJB-5-131 in MT
were due to its antioxidant properties in vivo, thenwe anticipatedhors
Figure 2. XJB-5-131 Suppresses Decline of
Weight Loss andMotor Function in a Mouse
Model of HD
(A) Weight of 57-week C57BL/6 wild-type (WT,
n = 15), untreatedHD150KI (- XJB, n = 7), and XJB-
5-131-treated HD150KI (+ XJB, n = 10) mice.
n, number of mice used. Data are mean ± SEM,
n = 7–15mice/group. **p < 0.01 using the unpaired
two-tailed Student’s t test.
(B and C) Rotarod performance (B) and grip
strength test (C) of animals at the age of 9, 28, and
57 weeks (Wk) with (+ XJB, n = 10) and without
( XJB, n = 7) XJB-5-131 treatment. Grasp test
was deemed a pass if the animals held the bar for
30 s (within three trials). Each age group of animals
was tested together and the results were ex-
pressed as % pass. n, number of mice used. Data
are mean ± SEM, n = 7–10. **p < 0.01 using the
unpaired two-tailed Student’s t test.that a reduction in oxidative damage to mtDNA would accom-
pany the improvement in motor function. To test the hypothesis,
we applied quantitative PCR (qPCR) to measure whether XJB-5-
131 altered the level of oxidative damage tomtDNA. Because the
movement of the polymerase on the template is blocked at
a lesion, qPCR amplification is inversely proportional to the
presence of DNA damage. HD150KI animals had a remarkable
increase in the load of oxidative mtDNA damage relative to
age-matched controls (Figures 3A and 3C). However, treatment
with XJB-5-131 led to a reduction in the damage burden (Fig-
ures 3A and 3C). Similarly, the abundance of mtDNA molecules
in HD150KI animals decreased by 36% relative to controls
(Figures 3B and 3D), consistent with previous suggestions that
mitochondrial biogenesis is impaired in HD animals (Johri
et al., 2012). Chronic treatment with XJB-5-131 restored the
mtDNA abundance to control levels (Figures 3B and 3D). Thus,
XJB-5-131 treatment not only decreased the lesion load in
mtDNA, but also prevented a decline in the relative abundance
of mtDNA in treated HD150KI animals relative to untreated litter-
mates (Figures 3A–3D).
XJB-5-131 Improves Mitochondrial Function
Because XJB-5-131 is a MT-targeted antioxidant, we tested
its effects on mitochondrial function. MT generate most of the
cell’s supply of ATP via the oxidative phosphorylation pathway,
which is measured by the oxygen consumption rate (OCR)
(Zhang et al., 2012). To determine the effects of XJB-5-131 on
OCR, we isolated synaptosomes from 57-week HD150KI ani-
mals and compared OCR before and after treatment with inhib-
itors of the electron transport chain (Figure 4A). Synaptosomes
are ‘‘pinched off’’ nerve terminals that harbor intact neuronal
MT and represent a simple and robust system to assess mito-
chondrial function within a physiological milieu (Choi et al.,
2009). Treatment of synaptosomes with 200 nM XJB-5-131 did
not induce a measureable change in the relative OCR of resting
synaptosomes from HD150KI animals (Figure 4B). Similarly,
XJB-5-131 had little effect on the relative decrease in OCR in
HD150KI synaptosomes after inhibition of ATP synthase with oli-
gomycin (Figure 4B). These results implied that XJB-5-131 had
minimal effects onmitochondrial metabolism in the resting state.Cell ReHowever, XJB-5-131 significantly improved mitochondrial re-
sponse to cellular stress as measured by the mitochondrial
membrane potential uncoupler, fluoro-carbonyl cyanide phenyl-
hydrazone (FCCP) (Figure 4B). FCCP destroys the proton
gradient in MT (Figure 4A) and uncouples electron transport
from ATP generation. Under these conditions, OCR rises as
the MT try to ‘‘keep up’’ with the energy demands of the cell.
The rise in OCR after FCCP treatment reflects the maximum
ability of MT to maintain energy production in response to acute
and chronic stress (Dranka et al., 2010), and is referred to
as mitochondrial spare respiratory capacity (SRC) or reserve
capacity (Figure S2). Indeed, treatment of striatal synaptosomes
with 1 mM and 10 mM solutions of XJB-5-131 elevated the
mitochondrial SRC, as measured by the approximately 2-fold
increase in OCR relative to untreated striatal synaptosomes (Fig-
ure 4C). XJB-5-131 treatment conferred a similar increase (2- to
3-fold) on the mitochondrial SRC in HD150KI cortical synapto-
somes (Figure S2) and in striatal synaptosomes isolated from
genetically matched C57BL/6 wild-type mice (Figure S2), indi-
cating that the improvement in the mitochondrial stress re-
sponse was neither limited to the striatum nor specific for the
HD mouse model.
XJB-5-131 Protects against DMNQ-Induced Loss of
Mitochondrial SRC
XJB-5-131 was designed as a targeted antioxidant. Thus,
we tested whether the protective effect of XJB-5-131 against
ROS-induced damage was due, at least in part, to the radical
scavenging activity of the compound. The ROS-inducer 2,3-di-
methoxy-1,4-naphthoquinone (DMNQ) is a non-thiol-capturing
and nonalkylating redox-cycling quinone that causes contin-
uous intracellular generation of H2O2 and subsequent oxidative
damage to MT (Figure 4D) (Parry et al., 2009). If XJB-5-131
was a radical scavenger, then we anticipated that it would pro-
tect against DMNQ-induced mitochondrial damage and would
alter the OCR in synaptosomes in response to DMNQ exposure.
As expected, treatment with oligomycin and FCCP increased
OCR in synaptosomes from 57-week HD150KI animals (Fig-
ure 4E). Addition of DMNQ, under these conditions, reduced
the SRC (Figure 4E), while administration of XJB-5-131 andports 2, 1137–1142, November 29, 2012 ª2012 The Authors 1139
Figure 3. XJB-5-131 Reduces mtDNA Damage and Maintains
mtDNA Copy Number
(A) Representative agarose gel of the amplification of a 10 kbmtDNA fragment
from WT, HD150KI, HD150KI + XJB-5-131 treated mice.
(B) Representative agarose gel of the amplification of a 116 bp mtDNA frag-
ment from WT, HD150KI, HD150KI + XJB-5-131 treated mice.
(C) XJB-5-131 decreases the levels of mtDNA lesions in the cerebral cortex of
HD150KI mice. Results were derived from three qPCR assays performed in
duplicate on each animal. The number of mice used was six, seven, and six for
control, HD150KI, and HD150KI + XJB-5-131, respectively. Data are mean ±
SEM (n = six or seven mice per group). **p < 0.01 using the unpaired two-tailed
Student’s t test.
(D) XJB-5-131 restores the abundance of mtDNA molecules in cerebral cortex
of HD150KI mice. Results were derived from two qPCR assays performed in
duplicate on each animal. The number of mice used was six, seven, and six for
control, HD150KI, and HD150KI + XJB-5-131, respectively. Data are mean ±
SEM (n = six or seven mice/group). **p < 0.01 using the unpaired two-tailed
Student’s t test.DMNQ together recovered the mitochondrial SRC to 90% of
control (Figure 4F). The XJB-5-131-induced increase in mito-
chondrial SRC was robust since subsequent addition of rote-
none and antimycin A, inhibitors of complex I and complex III
(Figure 4E), respectively, eliminated OCR differences among
treatment groups. These results suggested that the beneficial
effects of XJB-5-131were due, at least in part, to its radical scav-
enging activity, as designed.
DISCUSSION
Generic and naturally occurring antioxidants have been largely
ineffective against neurodegenerative diseases, although mito-
chondrial dysfunction has been strongly implicated as part of
the toxic mechanism (Johri and Beal, 2012; Mangialasche
et al., 2010). Here, we demonstrate that a synthetic, MT-targeted
XJB-5-131 imparts a remarkable suppression of motor decline,
inhibits weight loss, reduces mtDNA damage, maintains mtDNA
copy number, improves mitochondrial function, and enhances
neuronal survival in a knockin mouse model of HD. Collectively,
these findings imply that specific targeting of this synthetic anti-
oxidant to MT has beneficial effects both in vitro and in vivo, and
poise XJB-5-131 as a promising therapeutic compound.
XJB-5-131 has attractive properties. First, its delivery to MT
does not depend on the potential gradient across the inner mito-
chondrial membrane. Rather, selective localization of XJB-5-131
is accomplished via insertion of the b-turnmotif within the Leu-D-1140 Cell Reports 2, 1137–1142, November 29, 2012 ª2012 The AutPhe-Pro-Val-Orn segment into the mitochondrial membrane
(Fink et al., 2007). Thus, compromised MT with reduced mem-
brane potential would not exclude entry of XJB-5-131. Indeed,
we demonstrate that XJB-5-131 significantly improves mito-
chondrial function upon the treatment with the membrane
potential uncoupler FCCP. This is in contrast to potential-depen-
dent delivery of MT-targeted antioxidants. For example, MitoQ
and MitoVit E protect against glutathione depletion in cultured
fibroblasts from Friedrich’s ataxia patients, yet their enhanced
potency is abolished in cells pretreated with FCCP (Jauslin
et al., 2003). Moreover, the uptake of these potential-dependent
antioxidants is self-limiting, as there is inevitable depolarization
of MT upon accumulation of large amounts of cations in the
matrix (Kelso et al., 2001; Smith et al., 1999). Second, XJB-5-
131 readily crosses the plasma membrane while exogenously
supplemented vitamin E and CoQ10 are more lipophilic and
tend to be retained in cell membranes. Thus, these naturally
occurring compounds have difficulty in achieving pharmacolog-
ically significant intracellular concentrations (Jauslin et al., 2003;
Szeto, 2006).
XJB-5-131 not only enhances mitochondrial SRC but also
protects against DMNQ-induced loss of mitochondrial SRC.
Mitochondrial SRC is critical for survival and function of cells,
especially under conditions where cells undergo increased oxi-
dative stress or a sudden increase in energy demand (Desler
et al., 2012). For example, enhanced mitochondrial SRC favors
T cell survival after infection (van der Windt et al., 2012) and
loss of mitochondrial SRC renders cell death in the rotenone
model of PD with partial complex I deficiency (Yadava and Nich-
olls, 2007). In our experiments, the favorable properties of
MT-targeted XJB-5-131 suppressed pathophysiology without
obvious toxicity. Collectively, the beneficial effects of XJB-5-11
are promising, and warrant further investigations for its efficacy
in a broader set of MT-associated disorders and premature
aging phenotypes.
EXPERIMENTAL PROCEDURES
More detailed experimental procedures are provided in the Extended Experi-
mental Procedures.
Animals
We used a mouse model of HD (Lin et al., 2001), referred to as HD150KImice.
Genetically matched C57BL/6 mice were used as controls unless otherwise
stated. All procedures involving animals were performed in accordance with
the National Institutes of Health Guide for the Care and Use of Laboratory
Animals. Protocols were approved by the Lawrence Berkeley National Labora-
tories Animal Welfare and Research Committee.
XJB-5-131 Synthesis, Treatment, and Assessment of Motor
Functions
XJB-5-131 was synthesized as described previously (Wipf et al., 2005). A
fluorescent (FL) boron-dipyrromethene (BODIPY)-labeled XJB-5-131 was
prepared in an analogous fashion. HD150KI mice were intraperitoneally in-
jected 1 mg/kg of XJB-5-131 or phosphate buffered saline three times per
week from 7 to 57 weeks. Animals in each group (ten in the XJB-5-131
treatment group and seven in the untreatment group) were evaluated for ro-
tarod performance and grip strength at 9, 28, and 57 weeks on a Rota-Rod
apparatus (Ugo Basile, Comerio, Italy) according to a protocol described
previously (Trushina et al., 2006). See Extended Experimental Procedures
for details.hors
Figure 4. XJB-5-131 Improves Mitochon-
drial Function in HD150KI Animals
(A) Simplified diagram of electron transport chain
and its inhibitors. Rotenone, antimycin A, and oli-
gomycin are the inhibitors of complex I, complex
III, and ATP synthase, respectively. FCCP is an
ionophore, which allows re-entry of the protons
into the mitochondrial matrix and dissipates the
proton gradient.
(B) Representative profiles showing effects of
XJB-5-131 treatment on OCR under basal con-
ditions and upon injections of mitochondrial in-
hibitors in isolated striatal synaptosomes from
57-week HD150KI mice. Each profile represents
one independent biological experiment analyzed
in triplicate. Data are means ± SEM (n = 3). The
arrows indicate the injection of mitochondrial
inhibitors. Three independent experiments were
performed to obtain quantification of mitochon-
drial SRC presented in (C).
(C) Effects of XJB-5-131 treatment on SRC in
isolated striatal synaptosomes. SRC is defined
as the OCR difference between FCCP-induced
respiration and basal respiration. Data represent three independent experiments and each was performedwith fiveHD150KImice and analyzed in triplicate. Data
are mean ± SEM (n = 3). *p < 0.05, **p < 0.01 using the unpaired two-tailed Student’s t test.
(D) Schematic diagram illustrating the working hypothesis of DMNQ and XJB-5-131 within MT.
(E) Representative profiles showing effects of DMNQ on OCR in the absence and presence of XJB-5-131 under basal conditions and upon injection of mito-
chondrial inhibitors. The down arrows indicate the injection ofmitochondrial inhibitors. Each profile represents one independent biological experiment analyzed in
triplicate. Data are means ± SEM (n = 3). Three independent experiments were performed to obtain quantification of mitochondrial SRC presented in (F).
(F) XJB-5-131 treatment significantly improves mitochondrial SRC in 57-weekHD150KImouse striatal synaptosomes resulting from 1 mMDMNQ exposure. Data
are normalized to the control (in the absence of both XJB-5-131 and DMNQ) and are representative of three independent experiments. In each experiment, three
HD150KI mice were used and analyzed in triplicate. Data are mean ± SEM (n = 3). *p < 0.05 using the unpaired two-tailed Student’s t test.
See also Figure S2.Culture of Primary Striatal Neurons, MitoTracker Deep Red and
BODIPY-FL-XJB-5-131 Labeling, and Confocal Microscopy
Striatal neurons isolated on embryonic day 17 from HD150KI mice were culti-
vated as described elsewhere (Trushina et al., 2004). MitoTracker Deep Red
(Invitrogen, Carlsbad, CA, USA) and BODIPY-FL-XJB-5-131 were used to
label MT in live primary striatal neurons. Images were acquired on a Zeiss
LSM 710 inverted laser scanning confocal microscope. Image J and FIJI
was used for image analysis and quantification of cells. See Extended Exper-
imental Procedures for details.
Analysis of mtDNA Damage and Relative Abundance by Quantitative
PCR
The amplification of a 10 kb and a 116 bp mtDNA fragment was used to detect
lesions and abundance in mouse cerebral cortex as previously described
(Ayala-Torres et al., 2000; Santos et al., 2006). See Extended Experimental
Procedures for details.
Preparation of Striatal and Cortical Synaptosomes
Striatal and cortical synaptosomes were isolated as previously described
(Choi et al., 2009). Protein concentration was determined using the Bio-Rad
Bradford assay (Bio-Rad, Hercules, CA, USA). See Extended Experimental
Procedures for details.
Respiration of Synaptic MT
Respiration of synaptic MT was measured by the OCR using a Seahorse XF96
Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA) accord-
ing to the manufacturer’s instructions. See Extended Experimental Proce-
dures for details.
Induction of ROS with DMNQ
Freshly isolated synaptosomes were exposed to 1 mM DMNQ either in the
absence or presence of 10 mM XJB-5-131. Synaptosomes were plated on
the Seahorse PS 96-well microplate and spun down for 50 min at 4C. TheCell ReDMNQ exposure time was approximately 90 min before the OCR was
measured.
Statistical Analysis
Values were expressed as mean ± SEM, unless otherwise stated. p values
were obtained from the unpaired two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
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